AMLX - Mizuho downgrades Amylyx to Neutral after ALS trial setback
2024-03-18 09:35:20 ET
More on etc.
- Why 11%-Yielding BIZD's Run Of Beating The S&P 500 Is Likely Over
- Northwest Healthcare: 3 Takeaways From Q4 Results
- Arbor Realty: 13.3% 'Sucker Yield,' 3 Better Big-Dividend Strategies
- Nasdaq, S&P, and Dow advance as excitement builds for Nvidia GTC
- Goldman Sachs' Stephanie Cohen latest executive to depart from the firm - report